Sagent Pharmaceuticals Newswire

Sagent Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Sagent Pharmaceuticals.

Results 1 - 20 of 123 in Sagent Pharmaceuticals

  1. Athenex Announces The Promotion Of To The Position Of Chief Operating OfficerRead the original story

    Tuesday Feb 28 | BioSpace

    ... of experience. Previous to joining Athenex, he was the Founder, Chairman of the Board and CEO of Sagent Pharmaceuticals which was recently sold to Nichi-Iko Pharmaceutical Company. Mr. Yordon was one of the founders of American Pharmaceutical ...

    Comment?

  2. Plattsburgh company inks billion dollar dealRead the original story

    Feb 6, 2017 | WCAX-TV Burlington

    ... Manufacturing. Officials at SterRX announced Monday they inked a new one-billion dollar contract with Sagent Pharmaceuticals, a Japanese generic pharmaceutical company. The new contract will allow SterRx to manufacture a new line of drugs under the ...

    Comment?

  3. Anticoagulants Market 2016 Geographical Segmentation, Size, Trends, Growth and ForecastsRead the original story

    Jan 18, 2017 | Emailwire.com

    ... Eisai, GSK -Marathon Pharmaceuticals LLC -Ockham Biotech -Perosphere -Portola Pharmaceuticals -Sagent Pharmaceuticals Inc. -The Medicines Company -Urigen Pharmaceuticals Inc. -Valeant Pharmaceuticals Market driver -Growing prevalence of coagulation ...

    Comment?

  4. Global Age-Related Macular Degeneration Market 2016-2020; New Report LaunchedRead the original story w/Photo

    Jan 6, 2017 | SBWire

    ... - PanOptica - Pfizer - Promedior - QLT - Quark - Resolvyx Pharmaceuticals - RXi Pharmaceuticals - Sagent Pharmaceuticals - Santen Pharmaceuticals - Sanwa Kagaku Kenkyusho Market driver - Increasing reimbursement benefits for AMD drugs - For a full, ...

    Comment?

  5. Sagent Pharmaceuticals Inc (SGNT) Downgraded by Royal Bank Of Canada to HoldRead the original story w/Photo

    Dec 24, 2016 | AmericanBankingNews.com

    ... Cos. reissued an "overweight" rating and issued a $22.00 price target (down from $23.00) on shares of Sagent Pharmaceuticals in a research note on Wednesday, May 4th. JPMorgan Chase & Co. reissued a "hold" rating and issued a $18.00 price target on ...

    Comment?

  6. Future of Global Paclitaxel Injection Market: Report Forecast 2016 - 2026Read the original story w/Photo

    Dec 15, 2016 | SBWire

    ... market are Abbott Laboratories, Pfizer, Inc., Fresenius Kabi SE & Co. KGaA., Strides Arcolab Limited, Sagent Pharmaceuticals, Inc. Bristol-Myers Squibb Company, Celgene Corporation, Taj Accura Pharmaceuticals, Khandelwal Laboratories Pvt. Lmt., Luye ...

    Comment?

  7. Global Age-Related Macular Degeneration (AMD) Industry Will Grow...Read the original story

    Dec 11, 2016 | Emailwire.com

    ... Opthea Ophthotech PanOptica Pfizer Promedior QLT Quark Resolvyx Pharmaceuticals RXi Pharmaceuticals Sagent Pharmaceuticals Santen Pharmaceuticals Sanwa Kagaku Kenkyusho Market driver Increasing reimbursement benefits for AMD drugs For a full, ...

    Comment?

  8. This Canadian health-care company's bonds are yielding close to Venezuela's debtRead the original story w/Photo

    Nov 8, 2016 | The Globe and Mail

    Drug company Concordia International Corp. has appointed former Sagent Pharmaceuticals chief executive Allan Oberman as its new chief executive, effective Nov. 14. Drug company Concordia International Corp. has appointed former Sagent Pharmaceuticals chief executive Allan Oberman as its new chief executive, effective Nov. 14. Concordia International Corp.'s $4.9 billion debt-fueled acquisition spree is coming back to haunt the Canadian drugmaker's lenders. Bonds of the junk-rated company lost about $271 million since Monday, in their biggest two-day decline, after the company posted disappointing third-quarter earnings results and suspended its forecast.

    Comment?

  9. Report Published: "Global Age-Related Macular Degeneration Market 2016-2020"Read the original story w/Photo

    Nov 8, 2016 | SBWire

    ... -Ophthotech -PanOptica -Pfizer -Promedior -QLT -Quark -Resolvyx Pharmaceuticals -RXi Pharmaceuticals -Sagent Pharmaceuticals -Santen Pharmaceuticals -Sanwa Kagaku Kenkyusho Market driver -Increasing reimbursement benefits for AMD drugs -For a full, ...

    Comment?

  10. Another Canadian Drugmaker Trips After Debt-Fueled Buyout SpreeRead the original story

    Nov 8, 2016 | The Washington Post

    ... as it "assesses the business under new leadership." Allan Oberman, former chief executive officer of Sagent Pharmaceuticals Inc., will become CEO of Concordia on Tuesday, according to the statement. The company's founder, chairman and CEO, Mark ...

    Comment?

  11. Drug company Concordia International shares plunge more than 30 per centRead the original story

    Nov 7, 2016 | 680News

    ... stakeholders," the company said in a statement. The company announced earlier this month that former Sagent Pharmaceuticals chief executive Allan Oberman would take over as chief executive, effective Nov. 14. He succeeds Mark Thompson, who will also ...

    Comment?

  12. Concordia Bonds Plunge After Canadian Drugmaker Misses EarningsRead the original story

    Nov 7, 2016 | The Washington Post

    ... as it "assesses the business under new leadership." Allan Oberman, former chief executive officer of Sagent Pharmaceuticals Inc., will become CEO of Concordia on Tuesday, according to the statement. The company's founder, chairman and CEO Mark ...

    Comment?

  13. Former Sagent Pharmaceuticals chief executive named new Concordia chiefRead the original story

    Nov 2, 2016 | 680News

    Drug company Concordia International Corp. has appointed former Sagent Pharmaceuticals chief executive Allan Oberman as its new chief executive, effective Nov. 14. He succeeds Mark Thompson, who will also step down as chairman of Concordia's board of directors. The company announced in October that Thompson would be leaving after a replacement was found.

    Comment?

  14. Concordia taps former Sagent Pharmaceuticals as new CEORead the original story w/Photo

    Nov 2, 2016 | The Globe and Mail

    Drug company Concordia International Corp. has appointed former Sagent Pharmaceuticals chief executive Allan Oberman as its new chief executive, effective Nov. 14. Drug company Concordia International Corp. has appointed former Sagent Pharmaceuticals chief executive Allan Oberman as its new chief executive, effective Nov. 14. Drug company Concordia International Corp. has appointed former Sagent Pharmaceuticals chief executive Allan Oberman as its new chief executive, effective Nov. 14. He succeeds Mark Thompson, who will also step down as chairman of Concordia's board of directors. The company announced in October that Thompson would be leaving after a replacement was found.

    Comment?

  15. Concordia Announces New Leadership AppointmentsRead the original story

    Nov 1, 2016 | BioSpace

    ... experience, including his recent role as Chief Executive Officer of specialty pharmaceutical company, Sagent Pharmaceuticals, Inc. Sagent was sold to Nichi-Iko Pharmaceutical Co. Ltd., largest generic drug manufacturer, in a transaction that closed ...

    Comment?

  16. Anticoagulants Market in the US 2016 to 2020Read the original story w/Photo

    Oct 31, 2016 | PR-inside.com

    ... Eisai, GSK - Marathon Pharmaceuticals LLC - Ockham Biotech - Perosphere - Portola Pharmaceuticals - Sagent Pharmaceuticals Inc. - The Medicines Company - Urigen Pharmaceuticals Inc. - Valeant Pharmaceuticals Market driver - Growing prevalence of ...

    Comment?

  17. Sagent Pharmaceuticals Inc (SGNT) Stake Lowered by California Public Employees Retirement SystemRead the original story w/Photo

    Oct 24, 2016 | Daily Political

    California Public Employees Retirement System reduced its position in Sagent Pharmaceuticals Inc by 3.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission . The fund owned 45,900 shares of the company's stock after selling 1,500 shares during the period.

    Comment?

  18. State Board of Administration of Florida Retirement System Buys 840...Read the original story w/Photo

    Oct 21, 2016 | Daily Political

    State Board of Administration of Florida Retirement System increased its position in Sagent Pharmaceuticals Inc by 7.9% during the second quarter, Holdings Channel reports. The firm owned 11,531 shares of the company's stock after buying an additional 840 shares during the period.

    Comment?

  19. Concordia International Announces Closing of Senior Notes Offering and Appoints Allan Oberman to...Read the original story w/Photo

    Oct 13, 2016 | Freshnews

    ... including his most recent role as Chief Executive Officer of specialty pharmaceutical company Sagent Pharmaceuticals, Inc. Sagent was sold to Nichi-Iko Pharmaceutical Co. Ltd., Japan's largest generic drug manufacturer, in a transaction that closed ...

    Comment?

  20. Concordia lower by 4.45% as debt sale closes; adds board memberRead the original story w/Photo

    Oct 13, 2016 | Seeking Alpha

    ... " of Concordia's ( CXRX -4.2% ) strategic review. Added to the board is Allan Oberman, who was CEO of Sagent Pharmaceuticals (NASDAQ: SGNT ) until its sale at the end of August.

    Comment?